{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T06:43:44Z","timestamp":1776926624011,"version":"3.51.2"},"reference-count":50,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2026.2646079","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T06:02:48Z","timestamp":1776924168000},"page":"1111-1129","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission \u2013 a UK case study"],"prefix":"10.1080","volume":"29","author":[{"given":"Lieven","family":"Annemans","sequence":"first","affiliation":[{"name":"Interuniversity Center of Health Economic Research (ICHER), Department of Public Health and Primary Care, Ghent University","place":["Ghent, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3178-1622","authenticated-orcid":false,"given":"Erin","family":"Johansson","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Spaepen","sequence":"additional","affiliation":[{"name":"HaaPACS GmbH","place":["Schriesheim, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"van Hest","sequence":"additional","affiliation":[{"name":"Costello Medical","place":["Bristol, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josephine","family":"Grist","sequence":"additional","affiliation":[{"name":"Costello Medical","place":["London, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Zimner-Rapuch","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company","place":["Indianapolis, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2839-8404","authenticated-orcid":false,"given":"John P. H.","family":"Wilding","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool","place":["Liverpool, UK"]},{"name":"Clinical Sciences Centre, Liverpool University Hospitals NHS Foundation Trust","place":["Liverpool, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"e_1_3_3_2_1","unstructured":"World Health Organization (WHO). Obesity and overweight 2025 [cited 2025]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight"},{"key":"e_1_3_3_3_1","unstructured":"NHS Digital. Health Survey for England. 2021. Part 1. Available from: https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/health-survey-for-england\/2021\/overweight-and-obesity-in-adults"},{"key":"e_1_3_3_4_1","unstructured":"Obesity W. World Obesity Atlas. 2023. Available from: https:\/\/data.worldobesity.org\/publications\/WOF-Obesity-Atlas-V5.pdf"},{"key":"e_1_3_3_5_1","unstructured":"Institute for Global Change. Unhealthy numbers: the rising cost of obesity in the UK. Available from: https:\/\/www.institute.global\/insights\/public-services\/unhealthy-numbers-the-rising-cost-of-obesity-in-the-uk"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/2327-6924.12510"},{"key":"e_1_3_3_7_1","unstructured":"National Institute for Health and Care Excellence (NICE). Clinical Knowledge Summary: obesity. Available from: https:\/\/cks.nice.org.uk\/topics\/obesity\/"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410819"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404881"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2023.09.007"},{"key":"e_1_3_3_13_1","volume-title":"Tirzepatide matches dulaglutide for cardioprotection in type 2 diabetes","author":"Piper L.","unstructured":"Piper L. Tirzepatide matches dulaglutide for cardioprotection in type 2 diabetes. Springer Nature. 2025. Available from: https:\/\/www.springermedicine.com\/type-2-diabetes\/easd-2025\/surpass-cvot-tirzepatide-vs-dulaglutide-cardioprotection-t2d\/51483494."},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03288-3"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00316-4"},{"key":"e_1_3_3_16_1","unstructured":"National Institute for Health and Care Excellence (NICE). Tirzepatide for managing overweight and obesity. Technology appraisal guidance (TA1026). 2024. Available from: https:\/\/www.nice.org.uk\/guidance\/ta1026"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2021.10.001"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00837-x"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-020-00903-9"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.01.003"},{"key":"e_1_3_3_21_1","unstructured":"R Core Team. R: a language and environment for statistical computing; 2025. Available from: https:\/\/www.R-project.org\/."},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_3_3_23_1","unstructured":"National Institute for Health and Care Excellence (NICE). NICE health technology evaluations: the manual. Available from: https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/economic-evaluation-2#discounting"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.2838"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.2978"},{"key":"e_1_3_3_26_1","unstructured":"National Institute for Health and Care Excellence (NICE). Obstructive sleep apnoea\/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s. NICE Guidelines NG202. Available from: https:\/\/www.nice.org.uk\/guidance\/ng202\/chapter\/1-Obstructive-sleep-apnoeahypopnoea-syndrome"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.8.893"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-020-05196-7"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02597-w"},{"key":"e_1_3_3_30_1","unstructured":"National Institute for Health and Care Excellence (NICE). Semaglutide for managing overweight and obesity. Available from: https:\/\/www.nice.org.uk\/guidance\/ta875\/chapter\/1-Recommendations"},{"key":"e_1_3_3_31_1","unstructured":"National Institute for Health and Care Excellence (NICE). Liraglutide for managing overweight and obesity (TA664). Available from: https:\/\/www.nice.org.uk\/guidance\/ta664"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.122.009348"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.2337\/cd19-0101"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5019"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003232"},{"key":"e_1_3_3_36_1","unstructured":"National Health Service (NHS). National Health Service. 2021\/22 National Cost Collection data. Available from: https:\/\/www.england.nhs.uk\/costing-in-the-nhs\/national-cost-collection\/"},{"key":"e_1_3_3_37_1","unstructured":"National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: choosing medicines. Available from: https:\/\/www.nice.org.uk\/guidance\/ng28\/resources\/visual-summary-short-version-choosing-medicines-for-further-treatment-pdf-10956472095"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12647"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2021.10.181"},{"key":"e_1_3_3_40_1","unstructured":"National Institute for Health and Care Excellence (NICE). Tirzepatide for treating type 2 diabetes. Technology appraisal guidance (TA924). Available from: https:\/\/www.nice.org.uk\/guidance\/ta924"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2099"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101261"},{"key":"e_1_3_3_43_1","unstructured":"Poirrier J E Erringer J VBergemann R. R in HEOR modelling for HTA submissions: an assessment. Available from: https:\/\/www.parexel.com\/application\/files\/2917\/2729\/8142\/FY24_R_in_HEOR_Modelling_White_Paper_09-2024_v3.pdf"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15326"},{"key":"e_1_3_3_45_1","unstructured":"Data on File. SURMOUNT-1 Clinical Study Report. 2022."},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta13040"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.28.7.740"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23031"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.03.003"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X14565821"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.10360917"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2026.2646079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T06:02:51Z","timestamp":1776924171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2026.2646079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2026.2646079"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2026.2646079","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}